CA2478455A1 - Methodes de traitement de la sclerose en plaques - Google Patents

Methodes de traitement de la sclerose en plaques Download PDF

Info

Publication number
CA2478455A1
CA2478455A1 CA002478455A CA2478455A CA2478455A1 CA 2478455 A1 CA2478455 A1 CA 2478455A1 CA 002478455 A CA002478455 A CA 002478455A CA 2478455 A CA2478455 A CA 2478455A CA 2478455 A1 CA2478455 A1 CA 2478455A1
Authority
CA
Canada
Prior art keywords
subject
vla
antibody
multiple sclerosis
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478455A
Other languages
English (en)
Inventor
Michael Panzara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002478455A priority Critical patent/CA2478455A1/fr
Publication of CA2478455A1 publication Critical patent/CA2478455A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002478455A 2004-08-20 2004-08-23 Methodes de traitement de la sclerose en plaques Abandoned CA2478455A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002478455A CA2478455A1 (fr) 2004-08-20 2004-08-23 Methodes de traitement de la sclerose en plaques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/603,470 2004-08-20
CA002478455A CA2478455A1 (fr) 2004-08-20 2004-08-23 Methodes de traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
CA2478455A1 true CA2478455A1 (fr) 2006-02-20

Family

ID=35874774

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478455A Abandoned CA2478455A1 (fr) 2004-08-20 2004-08-23 Methodes de traitement de la sclerose en plaques

Country Status (1)

Country Link
CA (1) CA2478455A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104435821A (zh) * 2014-11-14 2015-03-25 吴永龙 一种治疗半身不遂的药物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104435821A (zh) * 2014-11-14 2015-03-25 吴永龙 一种治疗半身不遂的药物

Similar Documents

Publication Publication Date Title
AU2005277343B2 (en) Extended treatment of multiple sclerosis
US9533044B2 (en) Methods of treating inflammatory disorders using high concentration natalizumab compositions
HK1203055A1 (en) Treatment for multiple sclerosis
AU2005311635B2 (en) Delaying or preventing onset of multiple sclerosis
US20240317878A1 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
AU2011232775B2 (en) Extended Treatment of Multiple Sclerosis
AU2012202575B2 (en) Treatment for Multiple Sclerosis
CA2478456A1 (fr) Polytherapie
AU2012202571A1 (en) Delaying or Preventing Onset of Multiple Sclerosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20180116